Matica Biotechnology, a CDMO specializing in viral vector manufacturing for cell and gene therapies, reports that it signed a strategic commercial manufacturing agreement with a clinical-stage biotech company in the U.S. Matica officials say the partnership marks a significant milestone as Matica Bio initiates GMP production of viral vectors to support the development of a novel advanced therapy targeting a serious and underserved disease area.
Under the agreement, Matica Bio will provide technology transfer, process scale-up, analytical testing, and commercial-scale GMP manufacturing services. These activities will support Biologics License Application (BLA) submission and future commercial supply of the medicine.
“This collaboration reflects Matica Bio’s ability to support advanced therapeutic development from early development stage through to commercial manufacturing, all under strict regulatory compliance,” said Paul Kim, CEO of Matica Bio. “With Matica Bio’s advanced technology—such as our manufacturing platform built on the proprietary MatiMaxTM cell line, and advanced analytical capabilities empty/full capsid ratio analysis—we demonstrate expertise in delivering successful products for complex CGT programs in a continuously evolving market governed by strict regulatory requirements.”
